المؤلفون: Deepak Kakara Gift Kumar, Rama Rao Malla, Rahul Kumar Vempati, Shailender Gugalavath, Prasuja Rokkam

المصدر: Current Drug Metabolism. 21:33-43

مصطلحات موضوعية: Clinical Biochemistry, Breast Neoplasms, medicine.disease_cause, Zinc Finger Protein GLI1, 030226 pharmacology & pharmacy, Metastasis, 03 medical and health sciences, 0302 clinical medicine, GLI1, Radioresistance, Biomarkers, Tumor, medicine, Humans, Hedgehog Proteins, Neoplasm Metastasis, Transcription factor, Pharmacology, integumentary system, biology, Oncogene, Prognosis, medicine.disease, 030220 oncology & carcinogenesis, CYR61, Cancer research, biology.protein, Signal transduction, Carcinogenesis, Signal Transduction

الوصف: Glioma-associated oncogene homolog 1 (GLI1) is reported as an amplified gene in human glioblastoma cells. It is a krupple like transcription factor, belonging to the zinc finger family. The basic function of GLI1 is normal neural development at various stages of human. The GLI1 gene was first mapped on the chromosome sub-bands 12q13.3-14.1. Further, single nucleotide polymorphism is mostly observed in translating a region of 5’ and 3’- UTR of GLI1 gene in addition to two post-transcriptional splice variants, GLIΔN and tGLI. Additionally, it also regulates a plethora of gene which mediates crucial cellular processes like proliferation, differentiation, oncogenesis, EMT, and metastasis. It also regulates tumor tolerance, chemoresistance, and radioresistance. Aberrant expression of GLI1 predicts the poor survival of breast cancer patients. GLI1 is an essential mediator of the SHH signaling pathway regulating self-renewal of stem cells, angiogenesis, and expression of FOXS1, CYR61. GLI1 mediated HH pathway can induce apoptosis. Hence, GLI1 can be a future diagnostic, prognostic marker, and as well as a potent target of therapeutics in breast cancer.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7029d79904a31450fa49c2665b2b054Test
https://doi.org/10.2174/1389200221666200122120625Test

المؤلفون: Anil Kumar Badana, Seema Kumari, Rama Rao Malla, Prasuja Rokkam, Murali Mohan Gavara, Shailender Gugalavath, Deepak Kakara Gift Kumar

المصدر: Biophysical Reviews. 11:227-234

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Angiogenesis, medicine.medical_treatment, Biophysics, Review, 010402 general chemistry, medicine.disease_cause, 01 natural sciences, Targeted therapy, 03 medical and health sciences, Breast cancer, Structural Biology, Internal medicine, microRNA, medicine, Molecular Biology, Triple-negative breast cancer, 030304 developmental biology, 0303 health sciences, business.industry, medicine.disease, 0104 chemical sciences, Prognostics, Cancer biomarkers, business, Carcinogenesis

الوصف: Triple-negative breast cancer (TNBC) is the most aggressive and prevalent subtype of breast cancer in women worldwide. Currently, chemotherapy remains the main modality for the treatment at an early stage, as there is no approved targeted therapy for early TNBC. In this review, we investigate the use of microRNAs (miRNAs), which play a key role in the post-transcriptional regulation of genes involved in the key biological processes, namely proliferation, differentiation, angiogenesis, migration, apoptosis, and carcinogenesis. Here, we emphasize the importance of the recent advances related to miRNAs, involving diagnosis, prognosis, and treatment of TNBC. We focus on the development, optimization, and stabilization of miRNA-based drugs; improvement of miRNA delivery; and control of the off-target effects of miRNA therapeutics. We speculate as to which features may present themselves as promising approaches in the treatment of TNBC.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02347ec63825c17a7f8fdd35c2d511b2Test
https://doi.org/10.1007/s12551-019-00503-8Test

المؤلفون: Rakshimitha Marni, Kiranmayi Patnala, Rama Rao Malla, Deepak Kakara Gift Kumar

مصطلحات موضوعية: Drug, Chemotherapy, business.industry, medicine.medical_treatment, media_common.quotation_subject, Normal tissue, Cancer, Drug resistance, Disease, medicine.disease, Cancer research, Medicine, Efflux, Risk factor, business, media_common

الوصف: Gynecologic cancers are the cancers that originate in different reproductive organs of a woman. They are common between the age of 30 and 75 years. The major aggressive gynecologic cancers include cervical, ovarian, and endometrial cancers. Every type of gynecologic cancers are having distinctive signs, symptoms, and risk factors as well as various strategies for avoiding the disease conditions. All women are at threat for these cancers, and the danger increases with age and lifestyle activities. Chemotherapy is the first-line treatment option for major gynecologic cancers. However, the most common risk factor for major gynecologic cancers is the development of drug resistance to first-line therapeutic management/strategies. Noncoding RNAs are nonprotein coding transcripts which are differentially expressed among the malignant and benign tumors of gynecologic cancers as well as normal tissues. Deregulated expression of noncoding RNAs promotes or suppresses cancer initiation or progression as well as drug resistance. In addition, drug efflux mechanisms and their signaling mechanisms are also responsible for drug resistance in gynecologic cancers. This chapter attempts to describe the findings and drug resistance mechanisms with special reference to noncoding RNAs and drug efflux mechanisms in three aggressive gynecologic cancers of women.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::de6fcacb2c1de86292abd0f5cf818398Test
https://doi.org/10.1016/b978-0-12-824299-5.00018-6Test

المؤلفون: Maen Abdelrahim, Ala Abudayyeh, Elene Abzianidze, Luna Acharya, Sarfraz Ahmad, Saeed Ali, Abeer Arain, Riyaz Basha, Lakkakula V.K.S. Bhaskar, Lorna A. Brudie, Anjali Chandra, Begum Dariya, Akpedje Dossou, Aimen Farooq, Batoul Farran, Rafal Fudala, V. Gayathri, Nnamdi I. Gwacham, Nathan Hannay, Sana Hussain, Anum Jalil, Sundas Jehanzeb, Ketevani Kankava, Deepak Kakara Gift Kumar, Eka Kvaratskhelia, Andras G. Lacko, Rama Rao Malla, Hariharasudan Mani, Rakshimitha Marni, Ezek Mathew, Vikas Venkata Mudgapalli, Ibrahim N. Muhsen, Santoshi Muppala, Bhavani Nagarajan, Ganji Purnachandra Nagaraju, Maya Nair, Thomas A. Paterniti, Kiranmayi Patnala, Alexandra M. Poch, Mamoon Ur Rashid, Nirupama Sabnis, Deepika Sarvepalli, Evan A. Schrader, Ishna Sharma, Kasey Shepp, Swathi Sridhar, Aditi Talkad, Aman Ullah, Henu Kumar Verma, Jesse Wayson, James Wert, Hammad Zafar, Effa Zahid, Amy Zheng

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b9df2ec710df903049f34c56d3e630deTest
https://doi.org/10.1016/b978-0-12-824299-5.09987-1Test

المؤلفون: Deepak, Kakara Gift Kumar, Challa, Surekha, Suhasin, Ganta, Nagesewara Rao Reddy, Neelapu, Elansary, Hosam O., El-Ansary, Diaa O.

المصدر: Processes; Mar2020, Vol. 8 Issue 3, p301, 1p

مصطلحات موضوعية: TYPE 2 diabetes, BLOOD sugar, PLANT roots, PLANT extracts, LABORATORY rats, SALACIA oblonga, GLUCOSIDASE inhibitors, PHYTOCHEMICALS

مستخلص: Salacia oblonga is used to treat diabetes, hypocholesteremia, gonorrhea, rheumatism, asthma, inflammation, oxidative stress, etc. In the present study, the antidiabetic activity of S. oblonga methanolic root extracts collected from three geographical locations, viz., Eleshwaram (Andhra Pradesh), Thoothukudi (Tamil Nadu), and Karwar (Karnataka), was studied in vitro. Among the three extracts, S. oblonga root extracts from Eleshwaram showed maximum α-glucosidase and α-amylase inhibitory activities, indicating better antidiabetic activity. Acute toxicity studies of S. oblonga carried out in Albino Wistar rats showed no toxicity. Further, in vivo studies showed antidiabetic and antilipidemic activities in Albino Wistar rats with induced type II diabetes mellitus. Type II diabetes mellitus was induced in the experimental rats by intraperitoneal injection of nicotinamide and streptozotocin. The rats were orally fed different doses (ranging from 0 to 400 mg/kg body weight) of S. oblonga root extracts from Eleshwaram for 14 days. Blood glucose, lipid, bilirubin, and creatinine levels were analyzed on day 0, 7, and 14. The S. oblonga root extract from Eleshwaram decreased the glucose levels in a dose-dependent manner as well as the lipid, creatinine, and bilirubin levels in diabetic rats. Thus, the present study demonstrates antidiabetic and antilipidemic properties of S. oblonga root extracts. [ABSTRACT FROM AUTHOR]

: Copyright of Processes is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)